A phase II, multicenter, open label study of treatment escalation to ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and Brentuximab-Vedotin in advanced-stage Hodgkin Lymphoma patients with a positive interim PET scan after 2 ABVD cycles (OPTIMIST study)

drug protocol number
RC16/150
drug sponsor
KAIMRC
drug study
DOXORUBICIN HYDROCHLORIDE
drug trial site
NGHA-R
drug status
Ongoing
drug phase